Diartis receives investments from Index Ventures, Amunix
Diartis Pharmaceuticals also acquired the clinical-stage diabetes drug candidate VRS-859 (exenatide-XTEN) from Versartis and will use this initial funding to continue developing therapeutics for type 2 diabetes mellitus
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.